Icatibant Accord Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

icatibant accord

accord healthcare s.l.u. - icatibant acetate - angioødemer, arvelig - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

Ciambra Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

ciambra

menarini international operations luxembourg s.a. - pemetrexed dinatriumhemipentahydrat - carcinoma, non-small-cell lung; mesothelioma - antineoplastiske midler - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra er indisert som monoterapi for vedlikehold behandling av lokalt avansert eller metastatisk ikke-liten celle lunge kreft annet enn overveiende plateepitelkreft histology hos pasienter med sykdommen har ikke kommet umiddelbart etter platinum-basert kjemoterapi. ciambra er indisert som monoterapi for den andre linjen behandling av pasienter med lokalt avansert eller metastatisk ikke-liten celle lunge kreft annet enn overveiende plateepitelkreft histology.

Firazyr Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

firazyr

takeda pharmaceuticals international ag - icatibant - angioødemer, arvelig - hjertetapi - firazyr er indisert for symptomatisk behandling av akutte angrep hos arvelig angioødem (hae) hos voksne (med c1-esterase-inhibitormangel).

Icatibant Glenmark 30 mg Norvēģija - norvēģu - Statens legemiddelverk

icatibant glenmark 30 mg

glenmark arzneimittel gmbh - ikatibantacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 30 mg

Icatibant Newbury 30 mg Norvēģija - norvēģu - Statens legemiddelverk

icatibant newbury 30 mg

newbury pharmaceuticals ab - ikatibantacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 30 mg

Icatibant Teva 30 mg Norvēģija - norvēģu - Statens legemiddelverk

icatibant teva 30 mg

teva b.v. - ikatibantacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 30 mg

Icatibant Cipla 30 mg Norvēģija - norvēģu - Statens legemiddelverk

icatibant cipla 30 mg

cipla europe nv - ikatibantacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 30 mg

Engerix-B 10 mikrog/0.5 ml Norvēģija - norvēģu - Statens legemiddelverk

engerix-b 10 mikrog/0.5 ml

glaxosmithkline as - hepatitt b-virus overflateantigen, rekombinant - injeksjonsvæske, suspensjon - 10 mikrog/0.5 ml

Ebvallo Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

ebvallo

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Onivyde pegylated liposomal (previously known as Onivyde) Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

onivyde pegylated liposomal (previously known as onivyde)

les laboratoires servier - irinotecan anhydrous free-base - bukspyttkjertelblodsykdommer - antineoplastiske midler - behandling av metastatisk adenocarcinoma av bukspyttkjertelen, sammen med 5 fluorouracil (5 fu) og leucovorin (lv), i voksen pasienter som har kommet etter gemcitabine basert terapi.